Dr. Sterling is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
401 North Broadway Street
Weinberg BLDG
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Education & Training
Johns Hopkins UniversityFellowship, Medical Oncology, 2020 - 2022- Johns Hopkins UniversityResidency, Internal Medicine, 2017 - 2020
- Johns Hopkins University School of MedicineClass of 2017
Certifications & Licensure
MD State Medical License 2020 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis Start of enrollment: 2022 Nov 18
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha
Haematologica. 2024-11-14 - Antibody-Based Therapies for Peripheral T-Cell Lymphoma.Nazila Shafagati, Suman Paul, Sima Rozati, Cole H Sterling
Cancers. 2024-10-15 - 8 citationsTRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.Tushar D Nichakawade, Jiaxin Ge, Brian J Mog, Bum Seok Lee, Alexander H Pearlman
Nature. 2024-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
